Abstract C-terminal tensin-like (CTEN) gene is a member of the TENSIN gene family, involved in cell migration and localised at focal adhesion sites. This study was designed to explore the prevalence and clinical significance of CTEN expression in a large and well-characterised series (n = 1,409) invasive breast cancer (BC) cases with long term follow-up (median 11 years), using immunohistochemistry and tissue microarray. Moderate to strong cytoplasmic immunoreactivity for CTEN was observed in 90% of the studied cases. CTEN expression was significantly associated with poor prognostic variables including larger tumour size (P = 0.044), higher histological grade (P = 0.019), axillary nodal involvement (P = 0.035) and poor Nottingham Prognostic Index (P = 0.016). Significant associations were observed between increased CTEN expression and up-regulation of phosphorylated-Akt (P-Akt), PIK3 and N-cadherin proteins (P \ 0.001).
Introduction
Breast cancer (BC) is the second most common cause of cancer related death in women, after lung cancer, in the western world [1] . Worldwide, more than one million new cases of BC are diagnosed annually. In the UK, BC is now the most common cancer and almost 46,000 new cases are diagnosed every year [2] .
The TENSIN comprises three proteins (TNS1, TNS2 and TNS3), which are localised to cytoplasmic tail of integrin focal adhesion molecule, and are involved in various biological processes such as cell adhesion, migration, proliferation, differentiation, apoptosis and invasion [3] . They interact with several structural and signalling molecules such as vinculin, paxillin, Src, Focal Adhesion Kinase (FAK), phosphatidylinositol-3-kinase (PIK3) and Crkassociated substrate p130
CAS as well as actin [4] . The COOH-terminus Tensin-like molecule (CTEN) gene is the forth member of the TENSIN family, maps to chromosome 17q12-q21 and encodes a 715 amino acid protein [5] . It shares an extensive homology with other members at its Cterminal. However, in comparison to others, CTEN is a shorter polypeptide lacking the N-terminal actin-binding domain [3] . CTEN has a very restricted pattern of expression and was originally observed to be highly expressed in normal prostate and placenta [5] .
CTEN expression has been detected in various human tumours, but its role in cancer remains uncertain, because it behaves differently depending on the cancer tissue type. For example, others and we have reported that CTEN acts as an oncogene in colorectal cancer (CRC) and correlates with changed cell morphology and increased cell motility. This is complemented by decreased E-cadherin protein levels, resistance to staurosporine-induced apoptosis and increased colony forming properties [6, 7] . In addition, CTEN has been reported to have an oncogenic activity in thymomas, lung and gastric cancers, and in general, its over-expression has been associated with poor prognosis [8] [9] [10] . In BC, CTEN has been reported to stimulate mammary tumour migration through disruption of the link between integrins and cortical actin fibres at focal adhesion sites and its expression was highly linked to epidermal growth factor receptor (EGFR) activation [11] . Contrasting this, Lo et al. [5] reported down-regulation of CTEN in prostate cancer compared to normal prostate, and therefore CTEN might act as a tumour suppressor gene in this instance.
In the current study, we evaluated CTEN protein expression in a large series of BCs using immunohistochemistry on tissue microarrays (TMAs), in an attempt to assess if CTEN has prognostic significance on the outcome of patients with invasive BC.
Materials and methods

Patient selection and characterisation
Tissue microarrays (TMAs) were prepared from a series of 1,409 cases of primary operable invasive breast carcinoma from patients under the age of 70 years, diagnosed between 1987 and 1998 and entered into the Nottingham Tenovus Primary Breast Carcinoma Series. Patients' clinical and pathological data including patients' age, histological tumour type, primary tumour size, lymph node status, histological grade, Nottingham Prognostic Index (NPI), vascular invasion (VI) and development of local, regional and distant recurrence were available and maintained on a prospective basis. Survival data including Breast Cancer Specific Survival (BCSS) and Disease-Free Interval (DFI) were available. The BCSS is defined as the time (in months) from the date of the primary surgery to the time of death from BC. DFI is defined as the duration (in months) from the date of the primary surgery to the appearance of first local regional, recurrences or distant metastasis. Data on other biomarkers of known clinical and biological relevance to BC including oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), BRCA1, p53, phosphatidylinositol 3-kinase (PIK3), phosphoAkt473 (P-Akt), the cell-cycle-associated molecule Ki-67, N-cadherin, E-cadherin, P-cadherin, EGFR, HER1, HER2, basal and luminal cytokeratins (CKs) (CK5/6, CK14, CK18, CK19) were also available as previously described [12] [13] [14] [15] [16] [17] .
The median age of the patients was 55 years (range 18-70 years) with a median overall survival of 133 months (range 4-247 months) and the median time of event-free survival of 115 months (range 2-247 months). Distant recurrence occurred in 453 cases (31%), 395 (21%) patients died from BC, whilst 770 (44%) patients were alive at the end of follow-up.
This research was approved by Nottingham Research Ethics Committee 2 under the title of 'Development of a molecular genetic classification of breast cancer'. The Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al [18] , is followed throughout this study.
Immunohistochemistry
Four micro metre tissue TMA sections were immunohistochemically stained using the standard streptavidinbiotin complex method as previously described [18] . Water bath-induced method for retrieval of antigen was performed in EDTA buffer (Sigma), at pH 8.0. Primary mouse anti-CTEN (Abcam, ab57940) antibody [6] , diluted 1:75 (optimum working dilution) in normal swine serum (NSS), was applied to each slide, and incubated for 45 min at room temperature. Strept ABC complex (Dako) diluted in 1:100 in NSS was applied and incubated for 55 min. After washing with TBS, slides were incubated using freshly prepared diaminobenzidine (DAB; Sigma) solution for 10 min at room temperature. Slides were counterstained with haematoxylin (Dako). Negative controls were performed by omitting the primary antibody and substitution with a diluent. Whole tissue sections of HER2 positive cases were used as positive controls.
Scoring of immunohistochemical staining
Histochemical score (H-score) was used to assess the intensity and percentage of stained cells [19] . Only staining of the invasive malignant cells within the tissue cores was considered. Staining intensity was scored from 0, 1, 2 or 3, (0 no staining, 1 weak, 2 moderate, 3 strong). The percentage of positive cells was subjectively estimated and scored from 0 to 100%. Percentage staining was multiplied by corresponding intensity with products added representing the H-score ranging from 0-300. Immunostaining was evaluated by two Histopathologists (MI, AA) without prior knowledge of the clinicopathologic data or the patient outcome.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 statistical software (SPSS Inc. USA). Determination of the optimal CTEN cut-off was performed using X-tile bioinformatics software, version 3.6.1, 2003-2005, (Yale University, USA) [20] . Association between the CTEN immunoreactivity expression and different clinicopathological parameters was evaluated using Chi-squared test. Survival analyses were performed using the Kaplan-Meier plot with a log rank test to assess significance. Multivariate Cox hazard analysis was used to test the statistical independence and significance of the variables. A P-value of \0.05 was considered significant.
Results
The staining pattern for CTEN in breast tumour cells was homogenous cytoplasmic staining (Fig. 1) . In contrast, no tumour cell membrane or stromal expression of CTEN was detected in any specimen. Normal breast epithelium, entrapped in some cores, did not show any CTEN staining (Fig. 1) . The X-tile bio-informatics software was used to define optimal cut-off points of CTEN H-score values (\85 negative/low; C85 moderate/strong expression). This program randomly divides the total patients' cohort into two separate equal training and validation sets ranked by patients' follow-up time. The optimal cut-points were determined by locating the brightest pixel on the X-tile plot 
diagram of the training set. Statistical significance was tested by validating the obtained cut-point to the validation set. Using this cut-off point, 90% of studied tumours showed positive expression for CTEN.
Correlation between CTEN expression and clinicopathological parameters Table 1 summarises the associations between CTEN expression and clinico-pathological parameters. CTEN expression was significantly associated with larger tumour size (P = 0.044), higher tumour grade (P = 0.019), axillary lymph node metastasis (P = 0.035), occurrence of local and regional recurrence (P = 0.039, P = 0.042 respectively) and higher Nottingham prognostic index (NPI, P = 0.016). A significant association (P = 0.012) was found between CTEN expression and the histologic tumour type with more frequent expression of CTEN in invasive ductal carcinoma of no special type and invasive lobular carcinoma (92.9% and 92.6%, respectively). Furthermore, there was a significant association between increased CTEN expression and P-Akt, PIK3CA and Ncadherin (P \ 0.001). However, CTEN expression was not significantly associated with patients' age, menopausal status, vascular invasion, p53, HER2, EGFR, ER, MIB1, BRCA1 expression or any of Nielson's group subtypes [21] ( Table 2) .
Correlation between CTEN expression and patients' outcome
Kaplan-Meier curve demonstrated that patients with high CTEN expression had significantly poorer prognosis than those with low CTEN expression. Moreover, CTEN expression was associated with an increased likelihood to develop distant metastasis (P = 0.041), but this was not significantly associated with any particular metastatic site. Univariate survival analyses showed that patients with tumours positive for CTEN had shorter BCSS (P = 0.004; Fig. 2a ). Positive expression of CTEN also showed association with shorter distant metastasis-free interval (P = 0.041; Fig. 2b ). However, multivariate Cox proportional hazard analysis including tumour size, histological grade, lymph node stage, adjuvant hormonal, chemotherapy and CTEN expression showed that CTEN expression was not an independent predictor of BCSS and distant metastasisfree interval (P = 0.213, P = 0.874 respectively; Table 3 ). 
Discussion
In this study, the expression of CTEN protein was evaluated using immunohistochemistry in a large well-characterised cohort of BC cases, to evaluate its biological and prognostic relevance. To the best of our knowledge, this is the largest study to date pertaining to CTEN protein expression in BC. We found that CTEN expression was significantly associated with poor prognostic clinico-pathologic parameters, including larger tumour size, higher tumour grade, axillary lymph node metastasis and poor NPI. Moreover, our data showed that CTEN was more frequently over-expressed in invasive duct carcinoma NST and invasive lobular carcinoma, histologic types known to be associated with poor prognosis [22] . Recently, we have reported that CTEN acts as an oncogene in CRC and correlates with changed cell morphology and increased cell motility through repression of E-cadherin protein [6] . In support of this hypothesis, we have found a significant association, in the current study, between CTEN expression and lobular carcinoma that is known to be associated with loss of E-cadherin expression [23] . Although, CTEN expression did not show a significant association with E-cadherin protein expression in this series, there was a significant association with N-cadherin and a trend of positive association with P-cadherin expression; markers which have been reported to overexpress frequently in high-grade invasive breast carcinomas, conferring an increased motility of BC cells and being associated with tumour aggressiveness [24, 25] . A growing body of evidence has been shown that decreased expression of E-cadherin does not necessarily lead to induced cell motility in BC cells. In addition, forced expression of E-cadherin in invasive, N-cadherin-expressing MDA-MB-435 cells does not reduce their motility or invasive capacity. However, forced expression of N-cadherin in non-invasive, E-cadherin-positive BT-20 cells would confer the capacity to invade on these cells, even though they continued to express high levels of E-cadherin. Taken together, these data demonstrate that BC invasiveness might be correlated with N-cadherin expression rather than lack of E-cadherin expression as reported in CRC [26] .
Although CTEN expression showed a lack of association with other markers of aggressive tumour phenotype including EGFR and p53, it showed significant associations with PIK3CA and P-Akt which have been reported as oncogenic biomarkers associated with poor prognosis in BC [15, 27] . The close localisation of CTEN and PIK3 at the cytoplasmic tail of integrin raises the possibility that CTEN-mediated effect may be related to PIK3. Recently, we found that CTEN-forced expression and knock-down in CRC cell lines resulted in up-regulation and down-regulation of both focal adhesion kinase (FAK) and activated phosphorylated-FAK (P-FAK), respectively (unpublished data), indicating that CTEN may be considered as a key target in FAK-PIK3-Akt signalling pathway.
Our findings are in agreement with previous studies showing association between CTEN and both high tumour grade and the ability to metastasise to axillary lymph nodes [11] . Moreover, we showed that patients with CTEN overexpressing tumours had shorter BCSS and distant metastasis-free interval, supporting the oncogenic role of CTEN in BC. However, our data showed that CTEN expression was not significantly associated with increased expression of HER2 or EGFR and loss of ER, as shown previously [11] . This discrepancy may be due to the variations in the number of cases involved in both studies. They relatively investigated a small cohort of primary breast tumours compared with the present study.
In summary, we have shown that CTEN expression is a prognostic biomarker in BC, and its elevated expression is positively associated with markers of poor prognosis. The strong significant association between CTEN expression and both PIK3CA and P-Akt raised the possibility that CTEN may be involved in FAK-PIK3-Akt signalling pathway. Taken together, this information indicates that CTEN protein expression in BC could have a role in prognostic assessment of BC patients.
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